CTLA4 and melanoma: Snyder et al. [38] showed that a high number of neoantigen-producing mutations, defined as >100 mutations—a threshold that has been commonly reported for melanoma studies—indeed correlated with improved clinical benefit of CTLA-4 blockade in this cohort.